Brevan Howard Capital Management LP Makes New $550,000 Investment in Glaukos Co. (NYSE:GKOS)

Brevan Howard Capital Management LP acquired a new position in Glaukos Co. (NYSE:GKOS - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 3,671 shares of the medical instruments supplier's stock, valued at approximately $550,000.

Other hedge funds have also recently made changes to their positions in the company. Quadrant Capital Group LLC lifted its stake in Glaukos by 3.3% in the fourth quarter. Quadrant Capital Group LLC now owns 2,300 shares of the medical instruments supplier's stock valued at $345,000 after buying an additional 73 shares during the period. Mutual of America Capital Management LLC lifted its position in shares of Glaukos by 1.1% during the 4th quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier's stock valued at $1,252,000 after acquiring an additional 89 shares during the period. HighTower Advisors LLC boosted its stake in Glaukos by 2.8% during the fourth quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier's stock worth $495,000 after acquiring an additional 91 shares in the last quarter. Louisiana State Employees Retirement System grew its holdings in Glaukos by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier's stock worth $4,003,000 after purchasing an additional 100 shares during the period. Finally, Handelsbanken Fonder AB increased its stake in Glaukos by 0.7% in the fourth quarter. Handelsbanken Fonder AB now owns 14,700 shares of the medical instruments supplier's stock valued at $2,204,000 after purchasing an additional 100 shares in the last quarter. 99.04% of the stock is owned by institutional investors.

Glaukos Stock Performance

NYSE GKOS traded down $2.43 on Tuesday, hitting $92.21. 901,865 shares of the stock traded hands, compared to its average volume of 684,197. The firm has a market capitalization of $5.27 billion, a price-to-earnings ratio of -32.13 and a beta of 0.83. The business's fifty day moving average is $94.30 and its two-hundred day moving average is $126.82. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. Glaukos Co. has a 12 month low of $77.10 and a 12 month high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. The company had revenue of $106.66 million for the quarter, compared to analysts' expectations of $102.78 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. Glaukos's revenue was up 24.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.70) EPS. As a group, equities analysts anticipate that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Morgan Stanley cut their target price on Glaukos from $110.00 to $72.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Stifel Nicolaus lowered their target price on shares of Glaukos from $140.00 to $115.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Stephens dropped their price target on shares of Glaukos from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Friday, May 2nd. Needham & Company LLC decreased their price objective on Glaukos from $176.00 to $115.00 and set a "buy" rating for the company in a report on Thursday, May 1st. Finally, Piper Sandler dropped their target price on Glaukos from $180.00 to $165.00 and set an "overweight" rating on the stock in a report on Tuesday, April 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $134.67.

Insider Activity

In other news, insider Tomas Navratil sold 3,416 shares of the company's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the sale, the insider now owns 72,437 shares of the company's stock, valued at approximately $10,658,380.18. This represents a 4.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Alex R. Thurman sold 1,520 shares of Glaukos stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total transaction of $162,396.80. Following the completion of the transaction, the chief financial officer now owns 53,431 shares in the company, valued at approximately $5,708,568.04. The trade was a 2.77% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.80% of the company's stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.